Dopamine transporter in obesity: a meta-analysis

RUNNING HEAD

DAT in obesity

Kyoungjune Pak*, Keunyoung Kim, In Joo Kim

Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University
Hospital, Busan, Republic of Korea

Kyoungjune Pak* (Corresponding author)

Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University
Hospital, 179 Gudeok-ro, Seo-gu, Busan 49241, Republic of Korea

Office: +82-51-240-7389

Fax: +82-51-240-7442

ilikechopin@me.com

Keunyoung Kim

Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University
Hospital, 179 Gudeok-ro, Seo-gu, Busan 49241, Republic of Korea

nmpnuh@gmail.com

In Joo Kim

Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University
Hospital, 179 Gudeok-ro, Seo-gu, Busan 49241, Republic of Korea

injkim@pusan.ac.kr

ACKNOWLEDGEMENT

No

ABSTRACT

The brain plays a major role in controlling the desire to eat. This meta-analysis aimed to assess the association between dopamine transporter (DAT) availability, and obesity. We performed a systematic search of MEDLINE (from inception to November 2020) and EMBASE (from inception to November 2020) for articles published in English using the keywords “dopamine transporter,” “obesity,” and “neuroimaging”. Data were plotted for each radiopharmaceutical, and linear regression was used to describe the relationship between DAT ratio, and body mass index (BMI), spline curves were adopted to fit data between DAT ratio and BMI. Five studies including 421 subjects were eligible for inclusion in this study. Two studies with ^{123}I -FP-CIT, one with $^{99\text{m}}\text{Tc}$ -TRODAT, one with ^{123}I -PE21, and one with ^{18}F -FP-CIT were included. DAT availabilities from ENC-DAT project were higher than those from PPMI database both for caudate nucleus, and putamen. As there might be the inter-study variability, we calculated DAT ratio, after dividing DAT availabilities of subjects with overweight/obese BMI with mean DAT availabilities of subjects with normal BMI. In conclusion, we have shown that DAT availability of subjects with overweight/obesity was not different from those with normal BMI.

KEYWORDS

Dopamine Plasma Membrane Transport Proteins; Obesity; Neuroimaging

1. INTRODUCTION

Obesity rate has nearly tripled worldwide since 1975, and has become one of the major public health threats(2), as obesity is known to be a risk factor for malignancies of colon (2), pancreas (3), thyroid (4), liver (5), and uterus (6) as well as for cardiovascular diseases (7). Obesity arises from energy intake that chronically exceeds the energy expenditure (8). This excessive eating behavior as known as overeating has phenomenological similarities with excessive drug use in addiction (9). In this regard, researchers have focused on how the brain regulates eating behavior, and how obesity affects the brain (10, 11). Among the neurotransmitters synthesized in the brain, dopamine plays a major role in eating behavior as well as the executive function, motor control, and motivation (12-14). The role of the dopamine system in obesity, and eating behavior has been investigated with the help of neuroimaging using radiopharmaceuticals, as there is no direct method to measure dopamine levels in the human brain (11). Especially, dopamine receptor (DR) has been discussed widely with regard to obesity. However, the association between obesity and DR remains unclear due to the lack of agreement between the previous studies (15-18), probably due to the characteristics of the radiopharmaceuticals, or the study design.

Dopamine transporter (DAT) is a transmembrane protein that drives reuptake of extracellular dopamine into presynaptic neurons (19). Also, DAT is a major target for various pharmacologically active drugs (19). However, DAT has not been investigated widely in the view of obesity, in addition, the association of DAT with obesity showed the inconsistent results. In the study by Chen et al., DAT availability measured from ^{99m}Tc -TRODAT single-photon emission computed tomography (SPECT) was negatively correlated with body mass index (BMI) (20). However, other studies did not find the significant association between DAT availability and BMI (1, 21, 22). Therefore, we performed a meta-analysis to assess the association between DAT availability measured with radiopharmaceuticals, and obesity.

2. MATERIALS AND METHODS

2.1. Data Search and Study Selection

We performed a systematic search of MEDLINE (from inception to November 2020) and EMBASE (from inception to November 2020) for articles published in English using the keywords “dopamine transporter,” “obesity,” and “neuroimaging.” All searches were limited to human studies. The inclusion criteria were neuroimaging studies of DAT availability of striatum (striatum, caudate nucleus, putamen, ventral striatum) from healthy subjects in association with BMI. Reviews, abstracts, and editorial materials were excluded. Duplicate articles were excluded. If there was more than one study from the same institution, the study reporting information most relevant to the present study was included. Two authors performed the literature search and screened the articles independently, and discrepancies were resolved by consensus.

2.2. Data Extraction and Statistical Analysis

Two reviewers independently extracted the following information from the reports: first author, year of publication, country, radiopharmaceuticals, number of subjects, BMI, and DAT availability. Data were extracted by three methods; 1) BMI and the corresponding DAT availability were extracted from figures of each study using Engauge Digitizer, version 12.1 (<http://digitizer.sourceforge.net>), 2) the calculated DAT availability were downloaded from the shared database, 3) previously published data from our group were included. T-tests were done to compare the means of DAT availabilities from each database. Mean DAT availabilities of subjects with normal BMI ($18.5 \leq \text{BMI} < 25.0 \text{ kg/m}^2$) were calculated, and DAT availabilities of subjects with overweight/obese BMI (25.0 kg/m^2 or more) were divided with mean DAT availabilities of subjects with normal BMI, and defined as DAT ratio. Data were plotted for each radiopharmaceutical, and linear regression was used to describe the relationship between DAT ratio, and BMI, spline curves were adopted to fit data between DAT ratio and BMI. Data analysis was done using Prism 8 for macOS, version 8.3.1. (GraphPad Software, LLC, San Diego, CA, USA).

3. RESULTS

3.1. Study Characteristics

The electronic search identified 423 articles. Conference abstracts (n=183), animal studies (n=50), non-English studies (21), and studies that did not meet the inclusion criteria after screening the title or abstract (n=159) were excluded. After reviewing the full text of 10 articles, 5 studies including 421 subjects were eligible for inclusion in this study (1, 20, 22-24) (Figure 1). Two studies with ^{123}I -FP-CIT (22, 24), one with $^{99\text{m}}\text{Tc}$ -TRODAT (20), one with ^{123}I -PE21 (1), and one with ^{18}F -FP-CIT (23) were included. DAT availability was extracted from figures in 3 studies (1, 20, 22). In 3 studies that extracted data from figures, BMI and the corresponding DAT availability were extracted from 50 of 50 subjects (20), 114 of 123 subjects (22), and 33 of 33 subjects (1). The calculated DAT availability was downloaded from website of the shared database (Parkinson's Progression Markers Initiative, PPMI; <http://www.ppmi-info.org/>) in one study (24). Previously published data from our group was extracted in one study (23). Three studies included the subjects from each institution (1, 20, 23), and the study by van de Giessen et al. (22) analyzed the data of European databases of [123I]FP-CIT SPECT scans of healthy controls (ENC-DAT; <http://earl.eanm.org/cms/website.php?id=en/projects/enc-dat.htm>) project with 13 sites from 10 European countries without overlaps with PPMI database (24). Table 1 summarizes the study characteristics.

3.2. Association of DAT availability or DAT ratio with BMI

Data of 2 studies with ^{123}I -FP-CIT (22, 24) were plotted for each ROI (caudate nucleus, putamen) (Figure 2). DAT availabilities from ENC-DAT project (22) were higher than those from PPMI database (24) both for caudate nucleus ($p<0.0001$), and putamen ($p<0.0001$) (Figure 2). As there might be the inter-study variability, we calculated DAT ratio, after dividing DAT availabilities of subjects with overweight/obese BMI with mean DAT availabilities of subjects with normal BMI. Linear regression between BMI, and DAT ratio was not significant for both caudate nucleus ($p=0.4730$), and putamen ($p=0.5921$). Spline curves of DAT ratio from caudate nucleus, and putamen did not increase or decrease as BMI increases (Figure 3). In the study by Chen et al. with $^{99\text{m}}\text{Tc}$ -TRODAT, 14 subjects had BMI of $25\text{kg}/\text{m}^2$ or more (20). DAT ratio was lower than 1 in subjects

with BMI of 25kg/m² or more except for 1 subject, with the trend of decrease as BMI increases (Figure 4A). In the study by Thomsen et al. with ¹²³I-PE21, 21 subjects had BMI of 25kg/m² or more (1). Spline curves of DAT ratio from striatum did not increase or decrease as BMI increases (Figure 4B). As there were 6 subjects with BMI of 25kg/m² or more in the study by Pak et al., curve fitting for DAT ratio, and BMI could not be done (23).

4. DISCUSSION

In this study, we have shown that DAT availability of subjects with overweight/obesity was not different from those with normal BMI. Although DAT has not been discussed widely with regard to obesity, 5 studies of 421 subjects could be included in this study. Except for one study by Chen et al.(20), 4 studies have shown no significant association between DAT availability and BMI (1, 21-23). Chen et al. used ^{99m}Tc-TRODAT SPECT to measure DAT availability, and showed the negative correlation between DAT availability and BMI (20). ^{99m}Tc-TRODAT is a radiopharmaceutical based on a tropane structure, showing similar diagnostic performance with ¹²³I-FP-CIT to detect Parkinsonism (25). However, there might be the difference of binding capacity of radiopharmaceuticals in healthy subjects. Among 3 other studies that included in this meta-analysis, 2 studies with ¹²³I-FP-CIT (22, 24), and 1 study with ¹²³I-PE21 (1) did not show the significant correlation between DAT availability and BMI. In a previous study by Ziebell et al.(26), ¹²³I-FP-CIT and ¹²³I-PE21 showed the same target-to-background ratios, however, ¹²³I-FP-CIT gave rise to 3-fold higher counting rates per injected dose. From 2 studies with ¹²³I-FP-CIT, we extracted the data from the figure using the software (22), or the website of PPMI (24). In both of 2 studies, DAT availability was measured from striatal regions of caudate nucleus, and putamen (22, 24). However, as shown in figure 2, systematic difference between 2 studies might exist due to study design such as image acquisition, study population. Therefore, we plotted the data of DAT ratio of overweight/obese subjects to investigate the DAT availability adjusted for inter-study variability.. In the study by Thomsen et al.(1), ¹²³I-PE21 also did not change significantly according to BMI. However, the

numbers of overweight/obese subjects included in studies of Chen et al. with ^{99m}Tc -TRODAT (20), and Thomsen et al.(1) with ^{123}I -PE21 were small.

Dopamine plays a major role in modulating motivation and in reward processing (27). There are two major hypotheses regarding the role of dopamine. The first hypothesis, dopamine hyperresponsiveness, explains that there is a hypersensitivity to rewards which is related to an increased behavioural salience towards food leading to the excessive intake of highly palatable foods(28, 29). The second hypothesis, reward deficiency syndrome, states that subjects who are insensitive to rewards overeat to increase their endogenous dopamine levels (28, 29). Therefore, a nonlinear relationship of an inverted parabola has been proposed between the DR and BMI based on previous study (30). In mild obesity, the change in DR is not significant. However, with the onset of moderate obesity, the responsiveness of dopamine increases until the BMI rises to approximately 35 to 40 kg/m², following which a reward deficiency occurs, in severe obesity (28, 30). Brain dopamine neurotransmission is regulated by DAT, which drives reuptake of extracellular dopamine into presynaptic neurons (19). Previously, we used the glucose infusion to reflect food intake, and we have discovered that intravenous glucose loading induced substantial increases of striatal DAT availability by the action of insulin (23). From animal studies, insulin acts on striatal insulin receptors to enhance the surface expression of DAT through the PI3 kinase signalling pathway (31, 32). Therefore, food intake induced insulin signal works on the reward system through the dopamine function (32, 33).

In this study, we investigated the association of DAT availability with overweight/obesity, not with eating behavior. The state of overweight/obesity might be the results of excessive repetition of eating behavior. Therefore, the action of DAT on eating behavior might be different from that of the state of overweight/obesity. DAT is a major target for various pharmacologically active drugs. However, DAT is insensitive to the concentration of synaptic dopamine, as no change of DAT availability was observed after depletion of dopamine or release of dopamine, different from DR (34, 35). Therefore, no significant change of DAT in overweight/obesity may result from insensitivity of DAT to synaptic dopamine concentration, although synaptic dopamine concentration is increased or decreased in overweight/obesity. In addition, DAT may not have a role in the state of overweight/obesity, although it has an important role through the action of insulin in eating behavior.

This study has several limitations. First, a small number of studies were included in this meta-analysis. Therefore, the data from two studies of ^{123}I -FP-CIT could be pooled to analyze the role of DAT in obesity. Second, radiopharmaceuticals, image processing, and data analysis techniques are different across the studies included in this meta-analysis, which might impact DAT availability. However, to adjust the inter-study variability, we adopted DAT ratio, rather than DAT availability. Third, although two authors extracted the BMI and corresponding DAT availability from figures in the studies, the data may be inaccurate.

In conclusion, dopamine plays a main role in the reward system with regard to obesity. Compared to subjects with normal BMI, those of overweight/obesity did not have a different DAT availability.

Funding

None

CONFLICT OF INTEREST

Nothing to declare

AUTHOR CONTRIBUTION

Kyoungjune Pak; study design, write the manuscript, image analysis, statistical analysis

Keunyoung Kim; image analysis

In Joo Kim; image analysis, statistical analysis

DATA AVAILABILITY

The datasets generated during the current study are available from the corresponding author on reasonable request.

REFERENCES

1. Thomsen G, Ziebell M, Jensen PS, da Cuhna-Bang S, Knudsen GM, Pinborg LH. No correlation between body mass index and striatal dopamine transporter availability in healthy volunteers using SPECT and [123I]PE2I. *Obesity (Silver Spring)*. 2013; **21**(9): 1803-6.
2. Na SY, Myung SJ. [Obesity and colorectal cancer]. *Korean J Gastroenterol*. 2012; **59**(1): 16-26.
3. Gukovsky I, Li N, Todoric J, Gukovskaya A, Karin M. Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer. *Gastroenterology*. 2013; **144**(6): 1199-209 e4.
4. Mijovic T, How J, Payne RJ. Obesity and thyroid cancer. *Front Biosci (Schol Ed)*. 2011; **3555**-64.
5. Alzahrani B, Iseli TJ, Hebbard LW. Non-viral causes of liver cancer: does obesity led inflammation play a role? *Cancer Lett*. 2014; **345**(2): 223-9.
6. Gu W, Chen C, Zhao KN. Obesity-associated endometrial and cervical cancers. *Front Biosci (Elite Ed)*. 2013; **5**109-18.
7. Burke GL, Bertoni AG, Shea S, Tracy R, Watson KE, Blumenthal RS, Chung H, Carnethon MR. The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease: the Multi-Ethnic Study of Atherosclerosis. *Arch Intern Med*. 2008; **168**(9): 928-35.
8. Bellisle F, Drewnowski A, Anderson GH, Westerterp-Plantenga M, Martin CK. Sweetness, satiation, and satiety. *J Nutr*. 2012; **142**(6): 1149S-54S.
9. Kenny PJ. Common cellular and molecular mechanisms in obesity and drug addiction. *Nat Rev Neurosci*. 2011; **12**(11): 638-51.
10. Schlogl H, Horstmann A, Villringer A, Stumvoll M. Functional neuroimaging in obesity and the potential for development of novel treatments. *Lancet Diabetes Endocrinol*. 2016; **4**(8): 695-705.
11. Pak K, Kim SJ, Kim IJ. Obesity and Brain Positron Emission Tomography. *Nucl Med Mol Imaging*. 2018; **52**(1): 16-23.
12. Baik JH. Dopamine signaling in reward-related behaviors. *Front Neural Circuits*. 2013; **7**152.
13. Ravussin E, Bogardus C. Energy balance and weight regulation: genetics versus environment.

Br J Nutr. 2000; **83 Suppl 1**S17-20.

14. Lam DD, Garfield AS, Marston OJ, Shaw J, Heisler LK. Brain serotonin system in the coordination of food intake and body weight. *Pharmacol Biochem Behav.* 2010; **97**(1): 84-91.
15. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS. Brain dopamine and obesity. *Lancet.* 2001; **357**(9253): 354-7.
16. Karlsson HK, Tuominen L, Tuulari JJ, Hirvonen J, Parkkola R, Helin S, Salminen P, Nuutila P, Nummenmaa L. Obesity is associated with decreased mu-opioid but unaltered dopamine D2 receptor availability in the brain. *J Neurosci.* 2015; **35**(9): 3959-65.
17. Eisenstein SA, Bischoff AN, Gredysa DM, Antenor-Dorsey JA, Koller JM, Al-Lozi A, Pepino MY, Klein S, Perlmutter JS, Moerlein SM, Black KJ, Hershey T. Emotional Eating Phenotype is Associated with Central Dopamine D2 Receptor Binding Independent of Body Mass Index. *Sci Rep.* 2015; **5**11283.
18. Caravaggio F, Raitsin S, Gerretsen P, Nakajima S, Wilson A, Graff-Guerrero A. Ventral striatum binding of a dopamine D2/3 receptor agonist but not antagonist predicts normal body mass index. *Biol Psychiatry.* 2015; **77**(2): 196-202.
19. Vaughan RA, Foster JD. Mechanisms of dopamine transporter regulation in normal and disease states. *Trends Pharmacol Sci.* 2013; **34**(9): 489-96.
20. Chen PS, Yang YK, Yeh TL, Lee IH, Yao WJ, Chiu NT, Lu RB. Correlation between body mass index and striatal dopamine transporter availability in healthy volunteers--a SPECT study. *Neuroimage.* 2008; **40**(1): 275-9.
21. Nam SB, Kim K, Kim BS, Im HJ, Lee SH, Kim SJ, Kim IJ, Pak K. The Effect of Obesity on the Availabilities of Dopamine and Serotonin Transporters. *Sci Rep.* 2018; **8**(1): 4924.
22. van de Giessen E, Hesse S, Caan MW, Zientek F, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Guignard R, Akdemir UO, Knudsen GM, Nobili F, Pagani M, Vander Borgh T, Van Laere K, Varrone A, Tatsch K, Booij J, Sabri O. No association between striatal dopamine transporter binding and body mass index: a multi-center European study in healthy volunteers. *Neuroimage.* 2013; **64**61-7.
23. Pak K, Seo S, Kim K, Lee MJ, Shin MJ, Suh S, Im HJ, Park JJ, Kim SJ, Kim IJ. Striatal dopamine transporter changes after glucose loading in humans. *Diabetes Obes Metab.* 2020; **22**(1): 116-

- 22.
24. Parkinson Progression Marker I. The Parkinson Progression Marker Initiative (PPMI). *Prog Neurobiol.* 2011; **95**(4): 629-35.
25. Van Laere K, De Ceuninck L, Dom R, Van den Eynden J, Vanbilloen H, Cleynhens J, Dupont P, Bormans G, Verbruggen A, Mortelmans L. Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. *Eur J Nucl Med Mol Imaging.* 2004; **31**(8): 1119-27.
26. Ziebell M, Holm-Hansen S, Thomsen G, Wagner A, Jensen P, Pinborg LH, Knudsen GM. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. *J Nucl Med.* 2010; **51**(12): 1885-91.
27. Wang GJ, Geliebter A, Volkow ND, Telang FW, Logan J, Jayne MC, Galanti K, Selig PA, Han H, Zhu W, Wong CT, Fowler JS. Enhanced striatal dopamine release during food stimulation in binge eating disorder. *Obesity (Silver Spring).* 2011; **19**(8): 1601-8.
28. Kessler RM, Zald DH, Ansari MS, Li R, Cowan RL. Changes in dopamine release and dopamine D2/3 receptor levels with the development of mild obesity. *Synapse.* 2014; **68**(7): 317-20.
29. Verbeken S, Braet C, Lammertyn J, Goossens L, Moens E. How is reward sensitivity related to bodyweight in children? *Appetite.* 2012; **58**(2): 478-83.
30. van Galen KA, Ter Horst KW, Booij J, la Fleur SE, Serlie MJ. The role of central dopamine and serotonin in human obesity: lessons learned from molecular neuroimaging studies. *Metabolism.* 2018; **85**: 325-39.
31. Carvelli L, Moron JA, Kahlig KM, Ferrer JV, Sen N, Lechleiter JD, Leeb-Lundberg LM, Merrill G, Lafer EM, Ballou LM, Shippenberg TS, Javitch JA, Lin RZ, Galli A. PI 3-kinase regulation of dopamine uptake. *J Neurochem.* 2002; **81**(4): 859-69.
32. Stouffer MA, Woods CA, Patel JC, Lee CR, Witkovsky P, Bao L, Machold RP, Jones KT, de Vaca SC, Reith ME, Carr KD, Rice ME. Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward. *Nat Commun.* 2015; **6**: 543.
33. Kleinridders A, Pothos EN. Impact of Brain Insulin Signaling on Dopamine Function, Food Intake, Reward, and Emotional Behavior. *Curr Nutr Rep.* 2019; **8**(2): 83-91.
34. Kilbourn MR, Butch ER, Desmond T, Sherman P, Harris PE, Frey KA. In vivo

[11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations. *Nucl Med Biol.* 2010; **37**(1): 3-8.

35. Booij J, van Loon G, de Bruin K, Voorn P. Acute administration of haloperidol does not influence 123I-FP-CIT binding to the dopamine transporter. *J Nucl Med.* 2014; **55**(4): 647-9.

TABLES

Table 1. Studies included in a meta-analysis

Author	Year of publication	Country	Radiopharmaceutical	No. of subjects	ROI	Source of data extraction
Chen et al	2008	Taiwan	^{99m} Tc-TRODAT	50	Striatum	Figure
van de Giessen et al	2013	ENC-DAT project (13 sites from 10 European countries)	¹²³ I-FP-CIT	123	Caudate nucleus, putamen	Figure
Thomsen et al	2013	Denmark	¹²³ I-PE21	33	Striatum	Figure
Pak et al	2020	Republic of Korea	¹⁸ F-FP-CIT	33	Ventral striatum, caudate nucleus, putamen	Previously published data
PPMI		33 sites	¹²³ I-FP-CIT	167	Caudate nucleus, putamen	Website of the shared database

ROI, region of interest; VST, ventral striatum; ENC-DAT, European databases of [¹²³I]FP-CIT SPECT scans of healthy controls; PPMI, Parkinson's Progression Markers Initiative

FIGURE LEGENDS

Figure 1. Flowchart

Figure 2. Scatter plots of DAT availability and BMI; A. Caudate nucleus; B. Putamen

Figure 3. Scatter plots and spline curves of DAT ratio and BMI; A. Caudate nucleus; B. Putamen

Figure 4. Scatter plots of DAT ratio, and BMI; A. ^{99m}Tc -TRODAT; B. ^{123}I -PE21